Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

and development programs at the following events:

  • April 12 to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research (AACR) in Denver, CO.
  • April 24, 2009: Micromet will hold an R&D meeting in New York, NY for investors and analysts to provide a review of its product pipeline.
  • May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, FL.
  • June 4 to 7, 2009: Update on the phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
  • September 20 to 24, 2009: First interim data from a phase 1 clinical trial with MT110, an EpCAM-targeting BiTE antibody, in patients with metastatic gastrointestinal and lung cancers at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
  • December 5 to 8, 2009: Update on a phase 2 clinical trial with blinatumomab in ALL patients and final results from a phase 1 clinical trial in late stage NHL patients at the annual meeting of the American Society for Hematology (ASH) in New Orleans, LA.

Additional expected Milestones in 2009:

  • In the first half of 2009, we expect to initiate a randomized, controlled, multicenter phase 2 clinical trial for relapsed colorectal cancer patients after complete resection of liver metastasis with adecatumumab, an EpCAM-targeting human monoclonal antibody that we develop in collaboration with Merck Serono;
  • Before the end of 2009, we plan to initiate an additional p
    '/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... China is increasingly being recognized ... research industry. Clinicaltrial.gov statistics highlight the popularity of ... population; a high increase in infectious diseases; a ... pool of patients and a track record of ... China also presents challenges for the clinical research ...
(Date:8/16/2014)... Madison, Virginia (PRWEB) August 16, 2014 ... of NDA Partners LLC announced today that Agnes ... Premier Expert consultant. NDA Partners Premier Experts are ... enable them to bring extraordinary value to the ... implement critical solutions to help clients successfully develop ...
(Date:8/15/2014)... DUBLIN , Aug. 15, 2014 Research ... "Global non-GMO Food Market 2014-2018" report to their offering. ... stands for genetically modified organism, in this the scientist conducts ... genes from the DNA of an organism, such as a ... of the plant they want to alter or make genetic ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Former GlaxoSmithKline Senior Executive Agnes Westelinck Joins NDA Partners as a Premier Expert Consultant 2Global non-GMO Food Market 2014-2018: Key Vendors are Amy's Kitchen, Nature's Path, Organic Valley and The Hain Celestial 2Global non-GMO Food Market 2014-2018: Key Vendors are Amy's Kitchen, Nature's Path, Organic Valley and The Hain Celestial 3
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... showed remarkable immune responses in monkeys, following similarly strong, ... data from earlier animal studies. The data was presented ...
... the term "splitsville" usually means "check your prenup." ... from boron nitride nanotubes, "splitsville" could mean "happily ... National Laboratory (Berkeley Lab) and the University of ... University, have developed a technique in which boron ...
... HAYWARD, Calif., June 28, 2011 Intarcia Therapeutics, ... results of a phase 2 clinical study of ... for the treatment of type 2 diabetes at ... San Diego, California. (Logo:   http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO ...
Cached Biology Technology:Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 3Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 4Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 5Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 6Splitsville for boron nitride nanotubes 2Splitsville for boron nitride nanotubes 3Splitsville for boron nitride nanotubes 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 2Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 3Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 5
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
(Date:8/19/2014)... Rochelle, August 19, 2014A new ovoid structure discovered in ... clay, contains a variety of minerals, and shows evidence ... resulting melting of the permafrost and mixing of surface ... broad range of analytical studies to determine the origin ... for how this ovoid formed, point to the most ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Life on Mars? Implications of a newly discovered mineral-rich structure 2
... Doha, Qatar Urgent law enforcement action by governments ... crucial to addressing the illicit ivory trade, according to ... Detailed regional summaries of the data held in ... database on ivory seizures, highlight the failure of law ...
... ever before of how much radiation reaches sensitive tissues ... models of the human body being developed at the ... of computer simulation tools and 3-D patient models that ... said Wesley E. Bolch, Ph.D., a professor in the ...
... monster movies, but palaeontologists have discovered evidence of how an ... place 4 million years ago. Such fossil evidence ... of bite marks on an otherwise well-preserved dolphin skeleton, the ... that led to the death of the dolphin, and determined ...
Cached Biology News:New analysis points to ivory enforcement failures in parts of Africa, Asia 2Age, gender can affect risk to radiation treatment 2Age, gender can affect risk to radiation treatment 3Jaws -- 4 million BC 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: